Hematology-American Society of Hematology Education Program

Article	Citations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	73
Your chemo is no good here: management of high-risk MCL	70
Diagnosis and therapeutic decision-making for the neutropenic patient	63
On the horizon: upcoming new agents for the management of ITP	43
Mastocytosis demystified	41
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	40
Anticoagulation at the end of life: whether, when, and how to treat	38
Neurological manifestations of MGUS	35
Labor and delivery: DIC, HELLP, preeclampsia	34
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	33
Bispecific antibody therapies	32
Inpatient recognition and management of HLH	30
Recognizing, defining, and managing CAR-T hematologic toxicities	30
Has PD-1 blockade changed the standard of care for cHL?	29
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	28
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	26
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	25
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	25
Divergent paths: management of early relapsed follicular lymphoma	24
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	24
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	23
Fitness and frailty in myeloma	23
How to recognize and manage COVID-19-associated coagulopathy	23
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	23

New approaches to tackle cytopenic myelofibrosis	22
Optimizing outcomes in secondary AML	22
BV and beyond: how to incorporate novel agents into PTCL management	22
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	21
Troubleshooting heparin resistance	21
MGCS: where do we stand today?	20
Selecting initial therapy in CLL	20
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	20
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	20
How to assess hemostasis in patients with severe liver disease	20
How to manage hemostasis in patients with liver disease during interventions	19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	19
Consumptive coagulopathy in the ICU	19
Running interferon interference in treating PV/ET: meeting unmet needs	19
Hematology 2022—what is complete HLA match in 2022?	18
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	18
Hemophilia gene therapy: ushering in a new treatment paradigm?	18
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
Management of TKI-resistant chronic phase CML	18
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	17
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	17
Demystifying autoimmune HIT: what it is, when to test, and how to treat	17
How to diagnose and manage antiphospholipid syndrome	17
Management of limited-stage Hodgkin lymphoma	17
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	17
Managing therapy-associated neurotoxicity in children with ALL	17
What to use to treat AML: the role of emerging therapies	16
How to manage bleeding disorders in aging patients needing surgery	16
Atypical CML: diagnosis and treatment	16
Approaches to management of HIT in complex scenarios, including cardiac surgery	15
Management of marginal zone lymphomas	15
Special considerations in GI bleeding in VWD patients	15
CNS prophylaxis in aggressive B-cell lymphoma	14
Lower risk but high risk	14
Thrombosis questions from the inpatient wards	14
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
Organ function indications and potential improvements following curative therapy for sickle cell disease	14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	14
Transplant in AML with measurable residual disease: proceed or defer?	14
Alloimmunization and hyperhemolysis in sickle cell disease	14
Infectious complications and vaccines	14
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	13
Treatment of VTE in the thrombocytopenic cancer patient	13
Cytoreduction for ET and PV: who, what, when, and how?	13
When does a PNH clone have clinical significance?	13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	13

Thrombocytopenia in pregnancy	13
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	13
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Pegylated interferon: the who, why, and how	13
What makes a pediatric or young adult patient an appropriate transplant candidate?	12
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	12
Approach to the patient with suspected hypereosinophilic syndrome	11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	11
Clinical manifestations of telomere biology disorders in adults	11
Novel therapies upon failure of HMA plus venetoclax	11
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	11
Ph− ALL: immunotherapy in upfront treatment	11
Next-generation therapy for lower-risk MDS	11
Frontline treatment in CLL: the case for time-limited treatment	11
Should we use bisphosphonates to treat bone complications in sickle cell disease?	11
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	11
Whom should we treat with novel agents? Specific indications for specific and challenging populations	11
What else do I need to worry about when treating graft-versus-host disease?	11
Treatment of older adult or frail patients with multiple myeloma	10
The role of stem cell transplant (auto and allo) in PTCL and CTCL	10
Porphyria cutanea tarda: a unique iron-related disorder	10
In 2022, which is preferred: haploidentical or cord transplant?	10
Sequencing bispecific antibodies and CAR T cells for FL	10
IV iron formulations and use in adults	10
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	10
Managing side effects: guidance for use of immunotherapies in multiple myeloma	10
Warm autoimmune hemolytic anemia and the best treatment strategies	9
von Willebrand disease and heavy menstrual bleeding: when and how to test	9
When should we use it? The role of brentuximab vedotin in 2024	9
Clonal hematopoiesis in frequent whole blood donors	9
Diamond-Blackfan anemia	9
Immunology 101: fundamental immunology for the practicing hematologist	9
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	9
The approach of HMA plus VEN with or without BMT for all patients with AML	9
Barriers to accessing cellular therapy for patients receiving care in community practices	9
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	9
Are transplant indications changing for myelofibrosis?	9
Long-term prophylaxis: what are our options and how to define success?	9
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	8
Novel platelet products including cold-stored platelets	8
Risk-stratification in frontline CLL therapy: standard of care	8
Amyloid consults do not have to be vexing	8
Using disease-modifying therapies in sickle cell disease	8
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	8
Diagnosis and clinical management of enzymopathies	8
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	8
New definitions for antiphospholipid syndrome: ready for clinical use?	8
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	8
Management of Fanconi anemia beyond childhood	8
Sequencing therapy in relapsed DLBCL	8
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	8
Psychosocial and financial issues after hematopoietic cell transplantation	8
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	8
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	8
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	8
When to consider inherited marrow failure syndromes in adults	7
Heparin-induced thrombocytopenia and cardiovascular surgery	7
The first relapse in multiple myeloma: how to pick the next best thing	7
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	7
Double-hit lymphoma: optimizing therapy	7
Acute lymphoblastic leukemia in young adults: which up-front treatment?	7
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.	7
COVID-19 and thrombosis: searching for evidence	7
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	7
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	7
The intersection of sickle cell disease, stigma, and pain in Africa	7
Clonal evolution in inherited marrow failure syndromes predicts disease progression	7
Transplantation in CML in the TKI era: who, when, and how?	7
Novel clinical care models for patients with sickle cell disease	7
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	7
Renal manifestations of MGUS	7
Newborn screening initiatives for sickle cell disease in Africa	7
Multiple myeloma: a paradigm for blending community and academic care	7
New investigational combinations for higher-risk MDS	7
Diagnosis and clinical management of red cell membrane disorders	7
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	7

Mitigating and managing infection risk in adults treated with CAR T-cell therapy	7
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.	6
Ph+ ALL: new approaches for upfront therapy	6
Management of hemolytic transfusion reactions	6
Current use of bispecific antibodies to treat multiple myeloma	6
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	6
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	6
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	6
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	6
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	6
Challenges to successful outcomes in AYAs with ALL and potential solutions	6
Ph+ ALL in 2022: is there an optimal approach?	6
Potential and emerging therapeutics for HHT	6
Unexplained arterial thrombosis: approach to diagnosis and treatment	6
Sickle cell disease in India: the journey and hope for the future	6
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.	6
How immunodeficiency can lead to malignancy	6
Epidemiology and treatment of priapism in sickle cell disease	6
Cryptogenic oozers and bruisers	6
Maintenance strategies for relapse prevention and treatment	6
Cellular therapy for multiple myeloma: what's now and what's next	6
Late complications and long-term care of adult CAR T-cell patients	5
How to manage ITP with life-threatening bleeding	5
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	5
Optimal approach to T-cell ALL	5
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	5
Identifying and treating iron deficiency anemia in pregnancy	5
High-risk multiple myeloma: how to treat at diagnosis and relapse?	5
Dual-targeted regimens for the frontline treatment of CLL	5
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	5
Acute GVHD: think before you treat	5
Passive immune therapies: another tool against COVID-19	5
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	5
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	5
AL amyloidosis: untangling new therapies	5
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	5
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	5
Platelet components and bacterial contamination: hospital perspective 2022	5
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond	4
The 5 most frequently asked questions about factor Xa inhibitors	4
Incorporating gonadal health counseling into pediatric care of sickle cell patients	4
Current use of CAR T cells to treat multiple myeloma	4
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	4
Allogeneic transplantation for advanced acute leukemia	4
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	4
Givosiran: a targeted treatment for acute intermittent porphyria	4
Approaches to optimize outcomes in transplant recipients	4
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	4
The burden of myeloma: novel approaches to disease assessment	4
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	4
Advances in the management of α-thalassemia major: reasons to be optimistic	4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	4
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	4
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	4
Modified T cells as therapeutic agents	4
Inflamed—HLH, MAS, or something else?	4
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	4
When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow	4
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	4
Mutational screening to improve the transplantation decision-making process in MDS	4
Novel approaches to acute graft-versus-host disease prevention	4
Perioperative consultative hematology: can you clear my patient for a procedure?	4